Chul H Yu
Overview
Explore the profile of Chul H Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhong M, Gadek T, Bui M, Shen W, Burnier J, Barr K, et al.
ACS Med Chem Lett
. 2014 Jun;
3(3):203-6.
PMID: 24900456
LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of...
2.
Zhong M, Hanan E, Shen W, Bui M, Arkin M, Barr K, et al.
Bioorg Med Chem Lett
. 2010 Nov;
21(1):307-10.
PMID: 21109434
This letter describes the structure-activity relationship (SAR) of the 'right-wing' α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists. Novel (S)-substituted heteroaryl-bearing α-amino acids have been identified as replacements of...
3.
Zhong M, Shen W, Barr K, Arbitrario J, Arkin M, Bui M, et al.
Bioorg Med Chem Lett
. 2010 Jul;
20(17):5269-73.
PMID: 20655213
This letter describes the discovery of a novel series of tetrahydroisoquinoline (THIQ)-derived small molecules that potently inhibit both human T-cell migration and super-antigen induced T-cell activation through disruption of the...
4.
Zhong M, Bui M, Shen W, Baskaran S, Allen D, Elling R, et al.
Bioorg Med Chem Lett
. 2009 Aug;
19(17):5158-61.
PMID: 19646866
This Letter describes the discovery and key structure-activity relationship (SAR) of a series of 2-aminobenzimidazoles as potent Aurora kinase inhibitors. 2-Aminobenzimidazole serves as a bioisostere of the biaryl urea residue...
5.
Oslob J, Heumann S, Yu C, Allen D, Baskaran S, Bui M, et al.
Bioorg Med Chem Lett
. 2009 Feb;
19(5):1409-12.
PMID: 19186057
Compound 1 (SNS-314) is a potent and selective Aurora kinase inhibitor that is currently in clinical trials in patients with advanced solid tumors. This communication describes the synthesis of prodrug...
6.
Oslob J, Romanowski M, Allen D, Baskaran S, Bui M, Elling R, et al.
Bioorg Med Chem Lett
. 2008 Aug;
18(17):4880-4.
PMID: 18678489
This communication describes the discovery of a novel series of Aurora kinase inhibitors. Key SAR and critical binding elements are discussed. Some of the more advanced analogues potently inhibit cellular...
7.
Waal N, Yang W, Oslob J, Arkin M, Hyde J, Lu W, et al.
Bioorg Med Chem Lett
. 2005 Feb;
15(4):983-7.
PMID: 15686897
The identification, design, and synthesis of a series of novel sulfamide- and urea-based small-molecule antagonists of the protein-protein interaction IL-2/IL-2Ralpha are described. Installation of a furan carboxylic acid fragment onto...
8.
Raimundo B, Oslob J, Braisted A, Hyde J, McDowell R, Randal M, et al.
J Med Chem
. 2004 May;
47(12):3111-30.
PMID: 15163192
Fragment assembly has shown promise for discovering small-molecule antagonists for difficult targets, including protein-protein interactions. Here, we describe a process for identifying a 60 nM inhibitor of the interleukin-2 (IL-2)/IL-2...
9.
Dombroski M, Letavic M, McClure K, Barberia J, Carty T, Cortina S, et al.
Bioorg Med Chem Lett
. 2004 Mar;
14(4):919-23.
PMID: 15012994
The synthesis and in vitro p38 alpha activity of a novel series of benzimidazolone inhibitors is described. The p38 alpha SAR is consistent with a mode of binding wherein the...
10.
Letavic M, Barberia J, Carty T, Hardink J, Liras J, Lopresti-Morrow L, et al.
Bioorg Med Chem Lett
. 2003 Sep;
13(19):3243-6.
PMID: 12951101
A series of novel MMP-13 and TNF-alpha converting enzyme inhibitors based on piperazine 2-hydroxamic acid scaffolds are described. The TACE, MMP-1 and MMP-13 activity of these inhibitors as well as...